Package Insert: Information for the User
COLIROFTA CYCLOPLEGIC 10 mg/ml Eye Drop Solution
ciclopentolato hidrocloruro
Read this entire package insert carefully before starting to use this medication, as it contains important information for you.
It is an eye drop that contains ciclopentolato hydrochloride as its active ingredient, which dilates the pupil (has a mydriatic effect) and paralyzes the ability to focus the eyes (cycloplegic effect).
Colirofta Ciclopléjico is used for the exploration of the back of the eye and for a refraction examination (to measure errors in eye focus and detect refractive defects such as myopia, astigmatism, presbyopia, etc.) and in any condition where a pupil dilation effect (mydriasis) or paralysis of the muscle that produces accommodation (cycloplegia) is desired or when atropine cannot be used (produces a similar effect with a different action) in inflammatory processes of the uveal tract or the intermediate layer of the eye wall.
No use Colirofta Ciclopléjico:
Warnings and precautions
Consult your doctor or pharmacist before starting to use Colirofta Ciclopléjico.
Children
Elderly patients
Use with caution in elderly patients as they are more prone to increased eye pressure.
Other medications and Colirofta Ciclopléjico
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Especially, inform your doctor if you are using:
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Colirofta Ciclopléjico is not recommended during pregnancy.
During breastfeeding, the doctor should decide whether to interrupt breastfeeding or interrupt treatment with this medication, considering the benefit of breastfeeding for the child and the benefit of treatment for the mother.
Driving and operating machinery
You may notice blurred vision and light sensitivity for a prolonged period, such as 24 hours. Do not drive or operate machinery until these effects have disappeared.
COLIROFTA CICLOPLÉJICO contains parahidroxibenzoato de metilo and parahidroxibenzoato de propilo
It may cause allergic reactions (possibly delayed) because it contains parahidroxibenzoato de metilo (E-218) and parahidroxibenzoato de propilo (E-216).
Follow the exact administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The recommended dose is:
Ophthalmic route.
Adults
Instill 1 or 2 drops into the eye(s) approximately 40-45 minutes before the refraction examination. If necessary, this dose can be repeated at 5 or 10 minutes.
When seeking a sustained effect in general, 2 drops will be instilled three times a day.
You should exercise caution when using this medication in elderly patients as they are more prone to increased eye pressure.
Use in children
For refraction examination:
In the case of young children, see below.
After instillation, children should be closely observed for 30 minutes.
You should exercise caution when using this medication in children (see section 2).
This medication is not recommended for newborns and infants (especially premature infants and low-birth-weight infants) due to the risk of severe adverse reactions. See also the "Warnings and precautions" section in section 2, "If you use more Colirofta Ciclopléjico than you should" in section 3, and section 4 "Possible side effects".
The use of this medication in newborns and infants may cause feeding intolerance. Therefore, do not feed them until 4 hours after administration.
Usage recommendations:
If a drop falls outside the eye, try again.
If you are using other eye medications, wait at least 5 minutes between administering this medication and the other eye medications. Eye ointments should be administered last.
If you use more Colirofta Ciclopléjico than you should
You can remove it by rinsing your eyes with warm water. Do not apply more drops until it is back in use.
The symptoms of ocular overdose may include: skin redness and dryness (may present with rash in children), blurred vision, rapid and irregular pulse, fever, abdominal swelling in young children, convulsions, hallucinations, or loss of coordination in movements.
Symptomatic treatment should be provided.
The preferred antidote is physostigmine.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20 indicating the medication and the amount used, as severe reactions may occur (especially in children).
If you forgot to use Colirofta Ciclopléjico
Do not apply a double dose to compensate for the missed dose.
Apply a single dose as soon as you remember and continue with the next dose that was scheduled. However, if it is almost time for the next dose, do not apply the missed dose and continue with the next dose of your regular regimen.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
The following side effects have been observed:
Unknown frequency side effects (cannot be estimated from available data)
Other side effects:increased eye pressure and glaucoma in patients with a predisposition to acute angle closure, particularly in elderly patients; hyperactivity, tremor, anxiety, sedation, difficulty concentrating, increased heart rate, increased body temperature.
Other side effects in children
Additionally, this medicine may cause in children lack of coordination, seizures, skin rash, behavioral changes, psychiatric disorders, prolonged pupil dilation, abdominal distension in infants, increased heart rate, vasodilation, urinary retention, decreased intestinal motility, decreased salivary and sweat gland secretion, in the throat, bronchi, and nasal passages. Severe reactions are characterized by low blood pressure with progressive and rapid shallow breathing.
In newborns and infants, the use of this medicine may cause feeding intolerance (see section 3). In premature children, this medicine may cause necrotizing enterocolitis. In children, a local allergic reaction to this medicine has been observed, consisting of a skin rash.
The side effects of this medicine occur 20-30 minutes after its application and although they are usually transient, symptoms can last from 12 to 24 hours.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaRAM.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not store at a temperature above 25°C.
Do not use this medication after the expiration date that appears on the bottle and on the box after CAD. The expiration date is the last day of the month indicated.
To prevent infections, discard the bottle 4 weeks after first opening it.
Note the date of opening the bottle in the reserved box on the box.
Medicines should not be thrown down the drain or in the trash. Dispose of containers and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of containers and unused medications. By doing so, you will help protect the environment.
Composition of COLIROFTA CICLOPLÉJICO
Appearance of the product and content of the container
Colirofta Ciclopléjico is an eye drop solution. It is a transparent and colorless liquid that is presented in a box containing a dropper bottle (plastic bottle with a dispensing dropper) with a cap.
Each container contains 10 ml of eye drops.
Holder of the marketing authorization
Alcon Healthcare S.A.
World Trade Center Almeda Park
Plaça de la Pau s/n, Edificio 6, planta 3
08940 - Cornellà de Llobregat (Barcelona)
Spain
Responsible for manufacturing
Siegfried El Masnou, S.A.
C/Camil Fabra, 58
08320–El Masnou (Barcelona)
Spain
or
Alcon Laboratories Belgium
Lichterveld 3
2870 Puurs-Sint-Amands
Belgium
Last review date of this leaflet:June 2023
The detailed information of this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.